FDA Expands Approval of GSK’s Respiratory Syncytial Virus Vaccine

Adults as young as 18 can now receive the immunization.

The logo of the British multinational pharmaceutical company GlaxoSmithKline on top of its headquarters in London on Feb. 2, 2022. Justin Tallis/AFP via Getty Images

U.S. regulators have expanded the approval for GlaxoSmithKline’s vaccine against respiratory syncytial virus (RSV), the company said March 13.

Adults as young as 18 can now receive the vaccine, provided they are at increased risk of lower respiratory tract disease caused by RSV because of having conditions such as chronic liver disease or compromised immune systems.